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cense.Abstract Background: The differentiation of benign mesothelial cells from malignant tumor cells,
primary, or metastatic, in serous effusions based on cytomorphologic features alone can be prob-
lematic.
Purpose: This study was conducted to evaluate the utility of p53 and ki67 immunocytochemical
markers in differentiating benign from malignant tumor cells in serous effusions.
Patients and methods: Archival Papanicolaou-stained smears of 91 pleural and peritoneal effusions
were retrieved from Cytology Unit, Pathology Department, NCI, Cairo University between 2008
and 2010. Forty-one cases were positive for malignant cells and 50 cases were benign based on cyto-
morphologic features. Cases having doubt were excluded from the study. The slides were destained
and subjected to immunocytochemical staining for p53 and ki67. Histologic sections of colonic car-
cinoma and tonsillar tissue were used as positive control for p53 and ki67, respectively. Smears hav-
ing >5% positively stained nuclei for p53 were taken as positive and labeling indexP10% of ki67
was considered positive. Frequencies of the individual immunocytochemical stains; p53 and ki67, in
benign and malignant effusion as well as the combination of both stains were calculated.
Results: p53 immunostaining showed nuclear positivity in 31 out of 41 malignant effusions (75.6%)
and in 3 out of 50 benign effusions (6%), p< 0.005. p53 had 75.6% sensitivity, 94% speciﬁcity,
91.2% PPV, and 82.5% NPV. ki67 immunostaining was positive in 30 out of 41 malignant effusions
(73.2%) and in 17 out of 50 benign effusions (34%), p< 0.05. ki67 had 73.2% sensitivity, 66%
speciﬁcity, 63.8% PPV, and 75% NPV. Cases were then analyzed for combined immunoproﬁle
of p53 and ki67. Among the 24 cases that coexpressed both antigens, 22 cases (91.7%) were2607376/0104959148.
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156 N.H. Hafez, N.S. Tahounmalignant. Thirty two out of 34 cases (94.1%) that showed negative results for both antigens were
benign. For the cases that showed p53 immunostaining only, 9 out of 10 cases (90%) were malig-
nant. Fifteen out of 23 cases (65.2%) that showed ki67 immunostaining were benign.
Conclusion: Benign and malignant effusions showed signiﬁcantly different staining pattern for p53
and ki67. When used individually, p53 immunostaining can truly diagnose 75.6% and 94% of the
malignant and benign cases, respectively. ki67 immunostaining can correctly identify 73.2% and
66% of the malignant and benign cases, respectively. When used in combination, 91.7% of p53
and ki67 positive cases were malignant while 94% of p53 and ki67 negative cases were benign.
Hence they could be used when the cytomorphology fails to provide a deﬁnitive diagnosis.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Identiﬁcation of malignant, metastatic, or primary malignant
mesothelial cells in serous effusions using cytomorphology alone
is a well known diagnostic problem and is challenging to cytop-
athologists [1]. Reactive mesothelial cells in response to many
benign conditionsmay be difﬁcult to distinguish frommalignant
cells particularlywhen the former cells occur in clumps and show
various degree of cytologic atypia [2]. The cytologic features
commonly used to identify malignancy, including nuclear pleo-
morphism, macronucleoli, large cellular aggregates, papillary-
like tissue fragment, and cell in cell engulfment are helpful fea-
tures but have limited use in effusion because they may also be
present in ﬂorid reactive mesothelial hyperplasia [3].
Thus, the availability of techniques that would enhance the
diagnostic accuracy of routine cytological methods could be of
great clinical value. Ancillary techniques such as electron
microscope, ﬂow cytometry, and morphometry have been used
to solve the ambiguity in cytological differential diagnosis.
However, these are of limited use owing to the high cost, avail-
ability at only few specialized centers, requirement of highly
skilled personnel, and low sensitivity and speciﬁcity [4]. The
application of immunocytochemical technique to serous effu-
sion is more sensitive and speciﬁc than other methods and easy
availability of reagents for use in most of the laboratories
make it a good choice [5].
Some studies have suggested that the protein product of
tumor suppressor gene p53 has been found to be overexpres-
sed more frequently in malignant cells than reactive mesothe-
lial proliferation [6,7]. The proliferation cell markers have
been also used to aid the diagnosis of various benign and
malignant tumors and to predict patient’s survival for a vari-
ety of tumors. The proliferation marker ki67 may be useful in
separating mesothelial proliferation from malignant cells
[8,9].
p53 is a 53-kDa nuclear protein product of tumor suppres-
sor gene p53 that is located on the short arm of chromosome
17. It is involved in several cellular functions including tran-
scription, regulation of the cell cycle, DNA repair, and induc-
tion of apoptosis to preserve the genetic stability. Deletions or
mutations in p53 gene are common in human malignancies
(60%) leading to tumor growth [10]. The resultant mutated
p53 gene product has a longer half life than the normal protein
and increased stability of aberrant p53 proteins renders them
more readily detectable by immunostaining means. Thus the
highly increased level of mutated gene product in malignant
cells differentiates them from benign cells [11].ki67 antigen is a cell proliferation-related non-histone
nuclear protein that can be labeled with monoclonal antibody
MIB-1. The antigen is expressed in the nuclei of cells in active
phases of cell cycle (G1, S, G2, M) except resting phase (G0).
ki67 can be used to assess the growth fraction (the number of
cells in cell cycle) of normal, reactive, and neoplastic tissue
[12]. The percentage of ki67 positive cells (labeling index) is
usually low in benign lesions but increases in malignant
tumors. High ki67 index is an excellent marker to recognize
rapidly proliferating cell that would indicate malignancy and
might affect recurrence rate and survival [13].
The aim of the current study is to evaluate the utility of p53
and ki67 immunocytochemical markers in differentiating
benign mesothelial cell proliferation from malignant tumor
cells, primary, or metastatic, in serous effusions.
Patients and methods
Archival Papanicolaou-stained smears of 91 pleural and peri-
toneal effusions were retrieved from the Cytology Unit,
Pathology Department, National Cancer Institute, Cairo
University between 2008 and 2010. Forty-one cases were posi-
tive for malignant cells and 50 cases contained benign reactive
mesothelial hyperplasia. No cases having doubt were included
in the study. Effusions were labeled as benign or malignant on
the basis of cytological examination using the standard cyto-
morphologic features for cytologic diagnosis of serous effusion
[14].
Two cases of malignant effusions had conﬁrmatory histo-
logic diagnosis of malignant mesothelioma. The remaining
malignant effusions were conﬁrmed with the previous and/or
the current clinical and radiological ﬁndings reviewed from
the hospital records that showed:
(a) Presence of primary tumor elsewhere.
(b) Wide spread metastasis at the time of taping.
(c) Presence of bloody effusion in the absence of traumatic
tap.
(d) Presence of hemosidren laden macrophages on cytologic
examination that indicated chronic blood leaks.
(e) Rapid reaccumulation of the effusions after taping.
(f) Poor general condition (cachexia).
The slides were destained using the technique described by
Miller and Kubier [15]. The destained slides were subjected to
immunocytochemical staining for p53 and ki67 according to
the streptavidin–biotin–peroxidase technique using the mouse
monoclonal antibody Thermo Scientiﬁc Lab Vision, anti-p53
Figure 1 Reactive mesothelial cells in pleural effusion showing
variation in size, dense cytoplasm which tends to fade at the
periphery, smooth outer contour, and central or eccentric nucleus
(Papanicolaou stain 400·).
Role of P53 and ki67 immunocytochemistry in serous effusions 157Ab-6, clone DO-1 (dilution 1:30) and rabbit monoclonal anti-
body Thermo Scientiﬁc Lab Vision, anti-ki67, clone SP6 (dilu-
tion 1:100).
A positive control slide was run with each staining set to
ensure that all reagents were working properly. Histologic sec-
tions of colonic carcinoma and tonsillar tissue were used as
positive control for p53 and ki67, respectively; and a negative
control was used by substituting phosphate buffered saline
(PBS) for the primary antibody to evaluate non-speciﬁc stain-
ing and better interpretation of speciﬁc staining. All controls
yielded appropriate results. Only the nuclear immunoreactivity
for both p53 and ki67 was considered speciﬁc. Cytoplasmic
and membranous staining was considered non-speciﬁc. All
slides were immunocytochemically evaluated without any
information of clinical, cytopathological, or radiological data.
The result of p53 immunocytochemical stain was scored as:
negative if there was no nuclear staining in the examined
epithelioid cells, focal positive if there was nuclear staining in
65% of cells, and positive if there was nuclear staining in
>5% of cells. For ki67, the percentage of positively stained
nuclei out of the total epithelioid cell counted was estimated
(the labeling index) and categorized as: negative if no nuclear
staining in the examined epithelioid cells, low if there was nu-
clear staining in 610% of cells, moderate if there was nuclear
staining in 10–40% of cells, and high if there was nuclear stain-
ing in >40% of cells.
For all immunocytochemical stains, the resultswere indepen-
dently scored by the two cytopathologists and any discrepant
cases were reviewed at a double-headed microscope to achieve
consensus. Statistical analysis of the individual immunocyto-
chemical stains; p53 and ki67, in benign andmalignant effusions
as well as the combination of both stains were calculated using
statistical package for social science (SPSS), version 12.Figure 2 Metastatic high grade undifferentiated carcinoma cells
in pleural effusion showing pleomorphism, irregular nuclear
membrane, and chromatin clearance (Papanicolaou stain 400·).
Table 1 Clinico-pathological causes of the studied malignant
effusion cases.
Clinico-pathological causes Pleural Peritoneal Total
Malignant mesothelioma 2 0 2 (4.9%)
Breast carcinoma 17 0 17 (41.5%)
Lung carcinoma 11 0 11 (26.8%)
Ovarian carcinoma 0 6 6 (14.6%)
Colonic carcinoma 0 3 3 (7.3%)
Gastric carcinoma 1 1 2 (4.9%)
Total 31 10 41Results
The 41 cases of malignant effusion consisted of 26 females
(63.4%) and 15 males (36.6%) with an age range of 44–
76 years (mean age was 53.9 years and median age was
56 years). The 50 cases of benign effusion consisted of 28 males
(56%) and 22 females (44%) with an age range 31–62 years
(mean age was 45.2 years and median age was 49 years).
Twenty-nine cases of the 50 benign effusions (58%) were
developed in the pleural cavity (Fig. 1), while the remaining
21 cases (42%) were developed in peritoneal cavity. The malig-
nant effusions had developed in the pleural, 31 cases (75.6%)
(Fig. 2), and peritoneal, 10 cases (24.4%), cavities due to many
causes (Table 1).
For cases of malignant and benign effusions, p53 immunocy-
tochemical staining results are shown in Table 2 and Figs. 3–5.
Smears having >5% positively stained nuclei were taken as
positive. p53was signiﬁcantly more expressed in malignant than
benign effusions (p< 0.0001).
The p53 immunocytochemical results were then compared
with the clinico-cytological diagnosis of the corresponding
cases. The results are presented in Table 3.
p53 had 75.6% sensitivity, 94% speciﬁcity, 91.2% positive
predictive value (PPV), and 82.5% negative predictive value
(NPV) (Table 6).
The proliferation marker ki67 immunostaining was used to
determine the labeling index. For the studied malignant andbenign effusions, the ki67 labeling index is shown in Table 4
and Figs. 6–8. When using moderate to high labeling index
(P10%) as the cutoff point to be considered as positive, the
labeling index was signiﬁcantly higher in malignant effusions
compared with benign effusions (p< 0.001).
Table 2 Results of p53 immunocytochemical stain in the 91 studied malignant and benign serous effusions.
Clinico-cytological diagnosis p53 ICC score Total
Negative (0%) Focal (65%) Positive (>5%)
Malignant eﬀusions 2 (4.9%) 8 (19.5%) 31 (75.6%) 41
Benign eﬀusions 41(82%) 6 (12%) 3 (6%) 50
ICC, immunocytochemistry.
Figure 3 Metastatic undifferentiated carcinoma to pleural effu-
sion exhibiting positive nuclear staining for p53 (avidin–biotin–
peroxidase 400·).
Figure 4 Metastatic adenocarcinoma to peritoneal effusions
exhibiting positive nuclear staining to p53 (avidin–biotin–perox-
idase 400·).
Figure 5 Metastatic adenocarcinoma to pleural effusion exhib-
iting negative staining for p53, <5% positive nuclei (avidin–
biotin–peroxidase 400·).
Table 3 Comparative analysis of p53 immunocytochemical
staining results and clinico-cytological diagnosis.
Clinico-cytological diagnosis p53 ICC staining
Positive Negative
Positive 31 (91.2%) TP 10 (17.5%) FN
Negative 3 (8.8%) FP 47 (82.5%) TN
Total 34 (100%) 57 (100%)
ICC, immunocytochemistry; TP, true positive cases; FN, false
negative cases; FP, false positive cases; TN, true negative cases.
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with the clinico-cytological diagnosis of the corresponding
cases. The results are presented in Table 5.
ki67 had 73.2% sensitivity, 66% speciﬁcity, 63.8% positive
predictive value (PPV), and 75% negative predictive value
(NPV) (Table 6).
Cases were analyzed for combined immunoproﬁle of p53
and ki67 ( Table 7). When this comparative analysis wascorrelated with the clinic-cytological diagnosis, the results are
presented in Table 8.
From these results, when the studied cases revealed positive
immunostaining reaction for both markers used, there was
91.2% probability for malignancy. On the other hand, when
the studied cases did not express any immunostaining reaction
for the two markers used, 94.1% probability to be benign was
detected. When the studied cases expressed one marker only,
the probability of being benign or malignant was nearly equal
(48.5% and 51.5%, respectively).
Discussion
Several studies have suggested that p53 immunostaining does
not occur in benign mesothelium but is common in malignan-
cies involving serous effusions [7,16,17].
Table 6 Diagnostic reliability of p53 and ki67 immunocyto-
chemical staining on serous effusions.
Parameters p53 (CI) ki67 (CI)
Sensitivity 75.6% (59.5–87.6) 73.2% (56.9–85.7)
Speciﬁcity 94% (83.2–98.7) 66% (51.2–78.8)
PPV 91.2% (76.2–98.1) 63.8% (46.4–80. 3)
NPV 82.5% (70.0–91.2) 75% (62.1–85.9)
PPV, positive predictive value; NPV, negative predictive value; CI,
95% conﬁdence interval.
Table 4 Results of ki67 immunocytochemical stain in the 91 studied malignant and benign serous effusions.
Clinico-cytological diagnosis ki67 ICC labeling index Total
Negative (0%) Low (<10%) Moderate (10–40%) High (>40%)
Malignant eﬀusion 0 11 (26.8%) 22 (53.7%) 8 (19.5%) 41
Benign eﬀusions 21 (42%) 12 (24%) 17 (34%) 0 50
ICC, immunocytochemistry.
Figure 6 Metastatic undifferentiated carcinoma to pleural effu-
sion exhibiting positive nuclear staining for ki67 (avidin–biotin–
peroxidase 400·).
Figure 7 Metastatic undifferentiated carcinoma to pleural effu-
sion exhibiting positive nuclear staining for ki67 (avidin–biotin–
peroxidase 400·).
Figure 8 Metastatic adenocarcinoma to peritoneal effusion
exhibiting negative staining for ki67, <10% labeling index
(avidin–biotin–peroxidase 400·).
Table 5 Comparative analysis of ki67 immunocytochemical
staining results and clinico-cytological diagnosis.
Clinico-cytological diagnosis ki67 ICC staining
Positive Negative
Positive 30 (63.8%) TP 11 (25%) FN
Negative 17 (36.2%) FP 33 (75%) TN
Total 47 (100%) 44 (100%)
ICC, immunocytochemistry; TP, true positive cases; FN, false
negative cases; FP, false positive cases; TN, true negative cases.
Role of P53 and ki67 immunocytochemistry in serous effusions 159In an attempt to differentiate malignant from benign effu-
sions, p53 immunocytochemical stain had been advocated as a
malignant marker in 91 pleural and peritoneal serous effusions.
p53 was signiﬁcantly more expressed in malignant than benign
effusions (p< 0.0001). p53 positivity rate was found in 31 of
41 (75.6%) malignant effusions (true positive) and in only 3
of 50 (6%) benign effusions (false positive). Our ﬁndings are
in close comparison with the experience of Hall et al. [18] who
reported that 71% of their studied cytomorphologicallymalignant cases were p53 positive and none of the non-malig-
nant effusions showed p53 positivity. Akhtar et al. [19] reported
62% positivity rate in malignant effusions while no positivity
was recorded in benign cases. Our positivity rate was much
higher than that reported byMayall et al. [16] who reported that
Table 7 Comparison between p53 and ki67 immunostaining
results.
ki67 ICC results p53 ICC results Total
Positive Negative
Positive 24 23 47
Negative 10 34 44
Total 34 57 91
ICC, immunocytochemistry.
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nant effusions but was not found in any of 115 benign effusions.
Nearly the same results were concluded byHasteh et al. [20] and
Cagle et al. [21] who showed 46.7% and 48% positivity rate in
malignant effusions, respectively, and 2.2% and 0% positivity
rate in benign cases, respectively. The higher positivity rate in
the present study, compared to these studies, may be attributed
to the difference in the antibodies used where clone DO-1
MoAb had been used in the current study. VPp958 MoAb
was used by Hasteh et al. [20], clone BP53-12 MoAb was used
by Cagle et al. [21] and Do-7 MoAb was used by Mayall et al.
[16]. Also in Hasteh et al. study [20], all malignant cases had
mesothelioma and in Cagle et al. [21], 69% of their studied
malignant cases had mesothelioma, while in the present study
only two cases had malignant mesothelioma. Mayall et al. [22]
reported that malignant mesothelioma had low incidence of
p53 mutation. The difference in positivity rate may be also
attributed to the fact that there is no generalized accepted stan-
dard percentage to deﬁne the positivity for p53. The authors ap-
plied cutoff level>10%positive nuclei to be positive test. In the
current study smears having >5% positive nuclei were consid-
ered positive [16,20].
Stoetzer et al. [23] investigated four different monoclonal
antibodies against p53 for the diagnosis of malignancy in effu-
sions. They reported that the used antibodies reacted with 52–
75% of malignant effusions but also with 38–80% of benign
effusions. They concluded that the sensitivity and speciﬁcity
of p53 staining in effusions depend strongly on the antibody
used. They ﬁnally concluded that p53 staining did not improve
the identiﬁcation of malignant cells in serous effusions. The
same conclusion was reached by Walts et al. [7] who reported
p53 reactivity in 78% of malignant effusion, but they also re-
ported that the benign mesothelial cells in 14% of the studied
malignant effusions were also stained positively for p53. In
addition, p53 was positive in 73% of their studied benign effu-
sions. They ﬁnally concluded that p53 overexpression was not
necessarily indicative of malignancy.
Mullick et al. [24] demonstrated p53 positivity in only 41 of
75 (55%) malignant effusions, in 1 of 9 (11%) benign cases,
and in 3 of 19 suspicious cases. This positive benign case was
subsequently diagnosed as malignant mesothelioma on pleuralTable 8 Relation between clinico-cytological diagnosis an
benign effusions.
Clinico-cytological diagnosis +ve for both 
Malignant eﬀusion 22
Benign eﬀusion 2 3
Total 24 3biopsy, while 2 of the 3 positive suspicious cases showed non-
small cell lung carcinoma and poorly differentiated large cell
carcinoma. They concluded that positive staining in benign
and suspicious cells warrants further diagnostic evaluation of
the patients and negative p53 protein immunostaining does
not exclude malignancy. In the current work, we failed to
prove malignancy in the 3 (6%) positively stained benign cases.
One case lost follow up examination at the institute after tap-
ing, while the other two cases showed no malignancy on follow
up after reviewing of their hospital records.
Compared to our study, Pindzola et al. [25] investigated the
utility of p53 immunostaining to distinguish reactive mesothe-
lial cells from metastatic malignant ovarian carcinoma in ser-
ous effusions. They estimated both the intensity and the
percentage of positive nuclear staining. They concluded that
the staining intensity should be considered as a critical param-
eter in this separation, moderate and strong staining intensity
were considered truly positive. The percentage of nuclear stain-
ing, in their study, was less reliable parameter as 25% of be-
nign cases were positive by this assessment.
In the current work, 3 of 50 benign cases (6%) were positive
for p53 (false positive). The percentage of p53 positive cells in
studied benign cases (10–20%) was far lower than that seen in
malignant cases (45–90%). Although p53 aberrant accumula-
tion is usually detected in malignant tumors, it is also detected
in benign lesions characterized by hyperproliferation and
hyperplasia. Increased cell proliferation induced wild-type
p53 protein synthesis, which could regulate cell proliferation,
down regulate bcl-2, and activate apoptotic pathway [19]. King
et al. [26] mentioned that occasional overexpression of wild-
type p53 protein might be detected immunocytochemically in
benign lesions as a result of normal physiological DNA repair
in response to hyperproliferation or DNA damaging agents
causing false positive results. Levine et al. [27] attributed the
cause of p53 positivity in benign lesions to the type of the
monoclonal antibodies used as some antibodies could detect
both the wild- and mutant-type p53 proteins.
In the current work, there were 10 malignant cases (24.4%)
that failed to express p53 positivity (false negative cases). The
cause of false negative results could be related to technical fac-
tors that reduced or masked the p53 expression in malignant
tumors. These factors include methods of cell preparation
(smear versus cell block), methods of immunostaining (un-
stained or destained smears), interpretation subjectivity, and
the sensitivity of MoAb used [20].
In the present study, the sensitivity, speciﬁcity, PPV, and
NPV of p53 immunocytochemical stain were 75.6%, 94%,
91.2%, and 82.5%, respectively. Our results are comparable
to those of Kaﬁri et al. [10] who reported 70% sensitivity,
100% speciﬁcity, 100% PPV, and 77% NPV. Some previous
studies had reported moderate sensitivity with high speciﬁcity
for p53 markers. Akhtar et al. [19] in their similar effort
reported sensitivity, speciﬁcity, PPV, and NPV of 64%,d expression of p53 and ki67 markers in malignant and
ve for both +ve for p53 +ve for ki67
2 9 8
2 1 15
4 10 23
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ported 59% sensitivity and 100% speciﬁcity. Other previous
works had reported relatively lower sensitivity with high spec-
iﬁcity for p53 stain. Hasteh et al. [20] reported 47% sensitivity
and 98% speciﬁcity. Nearly similar results were reported by
Mayall et al. [16] who reported 48.6% sensitivity, 100% spec-
iﬁcity, 100% PPV, and 86.5% NPV.
The diagnostic value of ki67 immunostaining in human tu-
mors [29,30] as well as in benign and malignant mesothelial
proliferation [31] had been widely documented and accepted.
In the present study, there was signiﬁcant difference in ki67
expression between malignant and benign effusions (p< 0.001)
when using >10% labeling index as cutoff point. This is in
accordance with the experience of Scho¨nherr et al. [32] who re-
ported a higher ki67 labeling index in malignant than benign
effusions.
However, our data showed that ki67 is not completely reli-
able to differentiate benign from malignant effusions because
17 of 50 benign cases (34%) were positive (false positive cases)
and 11 of 41 malignant cases (26.8%) had <10% labeling in-
dex (false negative cases). The expression of proliferative cell
markers including ki67 in benign cases was explained by the
possible autocrine or paracrine growth factors that upregu-
lated the ki67 gene expression and hence increased the prolif-
erative indices [33]. This explanation was proved by the
demonstration of ki67 overexpression in normal breast and
pancreatic exocrine cells in other studies [34,35]. Hasteh et
al. [20] concluded that the cause of high labeling index in their
benign cases might be due to the presence of lymphocytes in
the effusions which were frequently positive and could cause
difﬁculty in estimation of labeling index by immunostaining.
In our study some benign cases contained inﬂammatory cells,
including lymphocytes, in the background. ki67 interpretation
was estimated among the total epithelioid cells counted only,
not inﬂammatory cells.
On the other hand, Saleh et al. [33] attributed the cause of
low labeling index in some malignant cases to the down-regu-
lation of ki67 gene by the effect of some autocrine and para-
crine uncertain factors. Sikora et al. [36] also attributed the
cause of the false negative cases to the low proliferative and
turnover activity in certain tumors or to technical factors that
cause reduction or masking of ki67 expression. These factors
included using destained slides for immunostaining that lead
to loss of some antigenicity by the destaining procedure. Kim-
ura et al. [37] concluded that percentages of immunostained
cells above and below, but close to, the cutoff point may ac-
count for the error in interpretation. They recommended that
the assessment of immunocytochemistry should be performed
using computer assistance to avoid wrong interpretations.
Other authors attributed the cause of the false negative cases
to the low cellularity of the metastatic epithelial cells in the
effusions [20].
In the present study, the sensitivity, speciﬁcity, PPV, and
NPV of ki67 immunocytochemical stain were 73.2%, 66%,
63.8%, and 75%, respectively. Our results are lower than
those reported by Taheri et al. [38] who demonstrated 88%
sensitivity and 94% speciﬁcity. Taheri et al. [31] in another
work evaluated the diagnostic value of ki67 and repp86 in
differentiation of benign mesothelial proliferation from
malignancy and reported 88% sensitivity and 92% speciﬁcity
for ki67. Cakir et al. [9] evaluated telomerase activity and
ki67 immunostaining to differentiate malignant from meso-thelial proliferation and reported 74% sensitivity and 86%
speciﬁcity for ki67. Kimura et al. [37] studied three prolifera-
tive markers (MCM7, Topo IIa, and ki67) to differentiate
malignant from mesothelial proliferation and reported
64.3% sensitivity and 92.9% speciﬁcity for ki67 using 30%
labeling index as cutoff point. Scho¨nherr et al. [32] in their
similar study on pleural cytology showed 77.8% sensitivity
and 90.9% speciﬁcity for ki67 when using a cutoff point of
>10%, but when they assumed a cutoff point of 25% as po-
sitive test, speciﬁcity became 100% but sensitivity was 25%.
The improvement of speciﬁcity with lowering of sensitivity
when increasing the cutoff point was also reported by Hasteh
et al. [20] who estimated 57% sensitivity and 56% speciﬁcity
for ki67 when using >10% as cutoff point. They reported
16% sensitivity and 91% speciﬁcity after using high labeling
index (>40%) as positive test.
In the present study, when assuming >25% labeling index
as cutoff point for positivity; all benign cases were correctly
diagnosed and only 25 of 41 malignant cases (61%) were true
positive. Thus the newly estimated sensitivity and speciﬁcity
were 61% and 100%, respectively. Like others, we found that
increasing the cutoff level could diagnose all benign cases but
miss more malignant cases resulting in increasing speciﬁcity
and decreasing sensitivity.
Hasteh et al. [20] concluded that each immunostaining mar-
ker has its own sensitivity and speciﬁcity when used alone. No
single antibody has been shown to be 100% sensitive and abso-
lutely speciﬁc for identiﬁcation of malignant cells in serous
effusions. They advised to use a panel of immunocytochemical
stains to make this distinction in cytological effusions. Consis-
tent with the role of p53 in controlling cellular proliferation, it
was hypothesized that there was an association between p53
positivity and the number of ki67 positive cells in different
neoplasms, suggesting that aberrant p53 expression is en-
hanced by cellular proliferation [23]. To verify whether the
simultaneous association of p53 and ki67 immunodetection
could help in differentiating malignant from benign effusions
with a high reliability, the comparative expression of both
markers was estimated and correlated with clinico-cytological
diagnosis. In the current work, it was important to recognize
that only 24 of the 91 studied cases (26.4%) coexpressed both
markers. It was found that for both p53 and ki67 positive
cases, 91.7% were malignant. For cases that were both p53
and ki67 negative, 94% were benign. For cases that were p53
positive and ki67 negative, 90% were malignant. For cases that
were p53 negative and ki67 positive, 65.2% were benign. p53
was considered as a more reliable malignant marker than
ki67. For cases that expressed ki67 only, they should be inter-
preted cytomorphologically in correlation with clinical and
radiological ﬁndings.Conclusion
Benign and malignant effusions showed signiﬁcantly different
staining pattern for p53 and ki67. When used individually,
p53 immunostaining can truly diagnose 75.6% and 94% of
the malignant and benign cases, respectively. ki67 immuno-
staining can correctly identify 73.2% and 66% of the malignant
and benign cases, respectively. When used in combination,
91.7% of p53 and ki67 positive cases were malignant while
162 N.H. Hafez, N.S. Tahoun94% of p53 and ki67 negative cases were benign. Hence they
could be used when the cytomorphology fails to provide a deﬁn-
itive diagnosis.
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